RESPIROLOGY is a prestigious academic journal that focuses on the field of Pulmonary and Respiratory Medicine, publishing high-quality research and comprehensive reviews that contribute significantly to the understanding and management of respiratory health. As a distinguished publication of WILEY, it has established a strong presence in the academic world with an impressive impact factor and ranked in the Q1 category, recognized for its influence and innovation in the field. RESPIROLOGY is committed to disseminating cutting-edge research from 1996 through 2024, appearing regularly in SCOPUS with a rank of #14 out of 155, placing it in the rarefied 91st percentile among its peers. The journal invites contributions from researchers, professionals, and students, fostering a collaborative space for advancing knowledge in pulmonary medicine. Although it does not offer open access, its readership spans globally, indicating the high regard in which it is held within the scientific community.

Minerva Respiratory Medicine is a prominent academic journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by EDIZIONI MINERVA MEDICA in Italy, this journal provides a vital platform for the dissemination of innovative research, clinical studies, and review articles that address the complexities of respiratory health. With an ISSN of 2784-8477 and an E-ISSN of 2724-6493, it serves as an open-access resource, allowing researchers, healthcare professionals, and students access to invaluable information without barriers. The journal is categorized in the fourth quartile of the 2023 rankings in the field of pulmonary and respiratory medicine, indicating its emerging role in the academic landscape. Despite its nascent status—converging from 2021 to 2024—Minerva Respiratory Medicine is committed to enhancing knowledge and practice in respiratory care, focusing on both innovative therapies and traditional approaches. With its aim to foster collaboration and communication among professionals in the field, this journal is an essential resource for those passionate about improving respiratory health outcomes.

Respiratory Investigation is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of Pulmonary and Respiratory Medicine. Since its inception in 2012, the journal has grown to become a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality research articles, reviews, and clinical studies. With a commendable impact factor and ranked in the Q2 category of Scopus' 2023 metrics, it stands at rank #57 out of 155 in its field, illustrating its importance and influence within the academic community. Although the journal operates on a subscription basis, it remains committed to disseminating essential findings that enhance the understanding and treatment of respiratory diseases. Set against the innovative backdrop of the Netherlands, Respiratory Investigation not only serves as a conduit for scholarly exchange but also plays a critical role in shaping future research directions and clinical practices.

The Egyptian Journal of Chest Diseases and Tuberculosis is a premier Open Access journal published by Wolters Kluwer Medknow Publications, focusing on the latest advancements in the fields of respiratory diseases, pulmonary medicine, and tuberculosis management. With an ISSN of 0422-7638 and an E-ISSN of 2090-9950, this journal aims to disseminate high-quality research, reviews, and clinical insights that advance the understanding and treatment of chest diseases. Since its transition to Open Access in 2018, the journal has garnered increased visibility, enabling researchers across the globe to contribute and access valuable content without barriers. Situated in India, the journal is dedicated to bridging the gap between clinical practice and research, emphasizing the significance of innovative therapeutic strategies and public health approaches in combating respiratory illnesses. We invite researchers, healthcare professionals, and students to engage with our publications as we continue to foster knowledge and foster collaboration within the global medical community.

The EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.

Lung India is a premier open-access journal dedicated to the dissemination of high-quality research in the field of Pulmonary and Respiratory Medicine. Published by Wolters Kluwer Medknow Publications, it has been forging a path in respiratory healthcare since its inception in 2004. With its impactful contributions to clinical practice and research, Lung India holds a solid position in the academic landscape, evidenced by its ranking in the Q3 quartile for Pulmonary and Respiratory Medicine as of 2023, and its Scopus rank of #99 out of 155. The journal is particularly important for researchers, clinicians, and students in India and beyond, providing a platform for the latest findings and developments in respiratory care, lung disease management, and innovative treatment methods. With a commitment to accessibility, Lung India aims to promote knowledge sharing among professionals and support the advancement of respiratory health. The journal is well-equipped to cater to a diverse audience, ensuring that vital research is readily accessible and impactful.

Annals of Thoracic Medicine is a prominent open-access journal, published by Wolters Kluwer Medknow Publications, focusing on the critical fields of cardiology, pulmonary and respiratory medicine, and surgery. With an ISSN of 1817-1737 and an E-ISSN of 1998-3557, this journal aims to disseminate cutting-edge research, clinical findings, and innovative practices that can significantly impact the health outcomes of patients dealing with thoracic diseases. Since its inception in 2006, it has established itself as a reputable source of knowledge, achieving Q2 quartile rankings in 2023 across its main categories. Currently ranked #126 in Medicine & Surgery and exhibiting a growing SCOPUS percentile, the journal plays an essential role in advancing the understanding and treatment of thoracic conditions. Open access options ensure that research is readily available to a global audience, facilitating collaboration and knowledge sharing among researchers, healthcare professionals, and students in the field.

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

Respiratory Medicine and Research, published by Elsevier, is a pivotal journal in the field of Pulmonary and Respiratory Medicine, dedicated to advancing the understanding and treatment of respiratory diseases. Since its inception in 2019, the journal has provided a platform for high-quality research, contributing significantly to the scientific community's knowledge base, as reflected in its impressive Q2 categorization in 2023. With a Scopus rank of #94 out of 155, placing it in the 39th percentile, this journal is essential for researchers, professionals, and students seeking the latest advancements in respiratory medicine. Although currently categorized as a non-open access publication, it remains accessible to those affiliated with institutions with subscriptions. Published in France, the journal aims to foster collaboration and innovation by highlighting original research, clinical studies, and comprehensive reviews that address pressing issues in respiratory health.

Chronic Respiratory Disease is a leading peer-reviewed journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by SAGE Publications Ltd since its inception in 2004, this open-access journal has been at the forefront of disseminating high-quality research aimed at addressing chronic respiratory conditions. With an impressive impact factor and classified as Q1 in the 2023 category of Pulmonary and Respiratory Medicine, it ranks an admirable #45 out of 155 in Scopus, placing it in the 71st percentile of its field. This journal features a diverse range of studies, reviews, and clinical insights that cater to researchers, healthcare professionals, and students alike, encouraging the exchange of innovative ideas and practices in respiratory disease management. Operating out of London, UK, Chronic Respiratory Disease exemplifies a commitment to openness, having transitioned to open access since 2017, thereby ensuring that pivotal research is readily accessible to a global audience engaged in the improvement of respiratory health.